Jonathan W. Engle

Tuning the Structural Properties of a Single-Domain Antibody Scaffold for Improved Fibroblast Activation Protein Targeting

This study engineers single-domain antibodies to improve targeting of FAP, showing that valency and molecular weight affect tumor uptake and biodistribution.

A MET-Targeted Variable New Antigen Receptor Theranostic for Non-Small Cell Lung Cancer

This paper develops a shark-derived VNAR-based theranostic agent for MET-altered NSCLC, showing imaging and therapeutic efficacy in preclinical models.

Targeting both GD2 and B7-H3 using bispecific antibody improves tumor selectivity for GD2-positive tumors

This paper develops a bispecific antibody targeting GD2 and B7-H3 to improve tumor selectivity and reduce toxicity in GD2-positive tumors.

Effects of clinically relevant radionuclides on the activation of a type I interferon response by radiopharmaceuticals in syngeneic murine tumor models

This study examines how different radionuclides affect the type I interferon response in tumor models and shows that 225Ac enhances immunotherapy response via STING-dependent mechanisms.

Development of FAP-targeted theranostics discovered by next-generation sequencing-augmented mining of a novel immunized VNAR library

The paper develops FAP-targeted theranostics using VNARs from a shark antibody library, showing high affinity and efficacy in vitro and in vivo.

Bispecific GD2 x B7-H3 Antibody Improves Tumor Targeting and Reduces Toxicity while Maintaining Efficacy for Neuroblastoma

Amyloid duration is associated with preclinical cognitive decline and tau PET

This study uses longitudinal amyloid PET data to estimate amyloid chronicity and finds it is linked to cognitive decline and tau burden in preclinical Alzheimer's disease.